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Abstract Despite favorable advancements in therapy
cancer is still not curative in many cases, which is often
due to inadequate specificity for tumor cells. In this
study derivatives of a short cationic peptide derived
from the human host defense peptide lactoferricin were
optimized in their selective toxicity towards cancer cells.
We proved that the target of these peptides is the
negatively charged membrane lipid phosphatidylserine
(PS), specifically exposed on the surface of cancer cells.
We have studied the membrane interaction of three
peptides namely LF11-322, its N-acyl derivative
6-methyloctanoyl-LF11-322 and its retro repeat deriv-
ative R(etro)-DIM-P-LF11-322 with liposomes mim-
icking cancerous and non-cancerous cell membranes
composed of PS and phosphatidylcholine (PC), respec-
tively. Calorimetric and permeability studies showed
that N-acylation and even more the repeat derivative of
LF11-322 leads to strongly improved interaction with
the cancer mimic PS, whereas only the N-acyl derivative
also slightly affects PC. Tryptophan fluorescence of
selective peptide R-DIM-P-LF11-322 revealed specific
peptide penetration into the PS membrane interface and
circular dichroism showed change of its secondary
structure by increase of proportion of b-sheets just in
the presence of the cancer mimic. Data correlated
with in vitro studies with cell lines of human melano-
mas, their metastases and melanocytes, revealing
R-DIM-P-LF11-322 to exhibit strongly increased spec-
ificity for cancer cells. This indicates the need of high
affinity to the target PS, a minimum length and net
positive charge, an adequate but moderate hydropho-
bicity, and capability of adoption of a defined structure
exclusively in presence of the target membrane for high
antitumor activity.
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Introduction
In 2008 more than 12.7 million people worldwide
were newly diagnosed with cancer accounting for 7.6
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factsheets/fs297/en/). Prospects of the World Health
Organization (WHO) suggest a further increase of new
cases in 2030 to 11 million deaths. Even though in the
last decades, much progress has been achieved
regarding chemotherapy, surgery, radiotherapy, tar-
geted therapy and combinations thereof there are still
many disadvantages and problems that have to be
handled. These are e.g., severe side effects due to non-
adequate specificity for tumor cells or drug resistance.
A promising strategy is the development of new
cancer therapies in the form of host defense peptides
(Hoskin and Ramamoorthy 2008; Papo and Shai 2005;
Riedl et al. 2011b) of various origins and derivatives
thereof. Host defense peptides are mostly cationic
amphipathic peptides, targeting the cell membrane by
electrostatic interactions with anionic molecules at the
cell surface (Riedl et al. 2011b). Though some
different types of anionic molecules are provided by
cancer cells that could account for the selectivity of
these membrane active peptides towards cancer cells
(Riedl et al. 2011b) a major target discussed is the
negatively charged phospholipid phosphatidylserine
(PS), which is reported to be exposed on the outer
leaflet of the cancer cell membrane (Connor et al.
1989; Ran et al. 2002; Riedl et al. 2011a; Schro¨der-
Borm et al. 2005; Utsugi et al. 1991; Zweytick et al.
2011a). In non-cancerous cells the outer leaflet of the
plasma membrane exhibits an overall neutral charge
due to its main components: the zwitterionic phos-
phatidylcholine (PC) and sphingomyelin (SM),
whereas PS together with phosphatidylethanolamine
(PE) only assembles the inner leaflet (Bevers et al.
1996). This regularly occurring asymmetric distribu-
tion of the major phospholipids between the two
membrane leaflets is well documented (Bevers et al.
1998; Zwaal and Schroit 1997) and is normally
maintained by an ATP-dependent-aminophospholipid
translocase (Seigneuret and Devaux 1984) and—
floppase (Zwaal and Schroit 1997). Further activation
of a third protein, the lipid scramblase, by influx of
Ca2? into the cytoplasm is reported to cause a rapid
transbilayer phospholipid mixing leading to a nearly
symmetric distribution across the membrane bilayer
(Zwaal and Schroit 1997). Thus, cellular changes like
depletion of ATP and/or influx of Ca2? into the
cytoplasm seem to be important factors accounting for
exposure of PS by cancer cells. Furthermore, as
proposed by Ran et al. (Ran et al. 2002) injury and
activation of tumor endothelium by cytokines and
reactive oxygen species might induce PS exposure of
tumor vessels. Also from lipid analytic studies in our
laboratory with melanoma and metastases thereof we
saw that not the overall PS content of cancer cells
increases compared to non-cancer cells, but seemingly
only the asymmetric PS distribution in the plasma
membrane gets lost (Riedl et al. 2011a).
Already in 1991 Utsugi et al. (1991) reported about
elevated expression of PS in the outer leaflet of human
tumor cells. In 2002 Ran et al. (2002) reported about
increased exposure of anionic phospholipids specifi-
cally on the surface of tumor blood vessels. Our recent
studies strongly supported these findings and demon-
strated that exposure of PS to the outer leaflet of
membranes is a general phenomenon for cancer plasma
membranes independently on cancer type and is also
characteristic for metastases and many cancer types
including those with poor outcome or treatability, like
malignant melanoma (Riedl et al. 2011a). PS exposure
would normally lead to recognition by macrophages
(Fadok et al. 1992) and dentritic cells (Martin et al.
1995) and consequently start of apoptosis which can
however be circumvented by cancer cells by different
ways (Miyashita and Reed 1993; Soengas et al. 2001).
Importantly we have also proven that cancer specific
PS exposure was no sign of apoptosis and not only true
for cancer cell lines but also for primary cancer cell
cultures (Riedl et al. 2011a). This yields a promising
overall marker for cancer as well as a specific target for
host defense peptides (Riedl et al. 2011a).
In the present study, we focused on the human host
defense peptide lactoferricin (LFcin) which is reported
to exhibit antimicrobial, antiviral, anti-inflammatory
and antitumor activities (Bezault et al. 1994; Gifford
et al. 2005; Vogel et al. 2002). Human lactoferricin
comprises amino acid residues 1–45 of the N-terminus
of human Lactoferrin (hLF). LF11, an 11 amino acid
fragment of hLFcin has already been optimized
regarding its activity against bacterial membranes
(Brandenburg et al. 2010; Zweytick et al. 2006, 2008,
2011b) and since bacterial as cancer membranes
comprise negatively charged phospholipids on their
surface and antimicrobially active peptides often also
possess antitumor activity (Wang et al. 2009) it was
reasonable to test LF11 derivatives, as LF11-322 and
others exhibiting antimicrobial activity (Zweytick
et al. 2011b) with cancer cell mimics and cancer cells.
One peptide family was selected for thorough
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investigations: LF11-322, its N-acylated derivative
6-MO-LF11-322 (6-methyloctanoyl-LF11-322) and
its ‘‘(retro) repeat’’-derivative R-DIM-P-LF11-322
(LF11-322-proline-LF11-322 retro). LF11-322 is an
LF11-derivative exhibiting good antibacterial activi-
ties and it has been shown in previous antibacterial
studies that N-acylation enhances the antibacterial
activity due to the higher hydrophobic potency
(Zweytick et al. 2006, 2011b). Since it was reported
by Yang et al. (2004) that for a potent antitumor
peptide a minimum length and minimum net positive
charge are needed for appropriate antitumor activity,
R-DIM-P-LF11-322 has been designed to fulfill these
requirements. The addition of the retro sequence to the
peptide moiety LF11-322 separated by a short spacer
(1 proline) aimed to create a sequence composed of the
peptide and its mirror image to increase amphipath-
icity and hence antitumor activity. In this article an
insight in the structural and mechanistic requirements
for a selective antitumor peptide like R-DIM-P-LF11-
322 is given. The peptide exhibited potent activity
against the cancer cell lines of melanoma (SBcl-2) and
melanoma metastases (WM164) that were previously
reported to expose PS (Riedl et al. 2011a), whereas for
the non-cancer cell lines such as melanocytes lacking






ine (Na-salt) (DPPS) and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-L-serine (Na-salt) (POPS) were
purchased from Avanti Polar Lipids, Inc. (USA), and
used without further purification. Stock solutions of
DPPC and POPC were prepared in CHCl3/CH3OH
(2:1, v/v), stock solutions of DPPS and POPS were
prepared in CHCl3/CH3OH (9:1, v/v) and stored at
-18 C. The amidated peptides LF11-322 (PFWRIR-
IRR-NH2, M = 1,298.6 g/mol), its N-6-methylocta-
noyl derivative 6-MO-LF11-322 (CH3CH2–CH2
(CH3)–(CH2)4–CO–NH-PFWRIRIRR-NH2, M =
1,438.9 g/mol) and R-DIM-P-LF11-322 (PFWRIR-
IRRPRRIRIRWFP-NH2, M = 2,677.4 g/mol) were
purchased from NeoMPS, Inc. (San Diego, CA,
USA). The purities were [96 % as determined by
RP-HPLC. Peptides were dissolved in Acetic acid
(0.1 %, v/v) at a concentration of 3 mg/ml. Peptide
solutions were stored at 4 C and concentrations were
determined by measurement of UV-absorbance of
tryptophan at 280 nm. ANTS (8-aminonaphthalene-
1,3,6-trisulfonic acid, disodium salt) and DPX (p-
xylene-bis-pyridinium bromide) used for permeability
studies were purchased from Molecular Probes
(Eugene, OR). Sodiumdodecylsulfate (SDS) and dod-
ecylphosphocholine (DPC) used for CD measurements
were purchased from Carl Roth GmbH&Co (Kar-
lsruhe, Germany) and Avanti Polar Lipids, Inc. (USA),
respectively.
Cell lines and culture
The melanocytic cell lines were kindly provided by
Dr. Meenhard Herlyn (The Wistar Institute, Philadel-
phia, PA). Melanoma cell lines from primary (SBcl-2)
and metastatic (WM164) lesions were grown in RPMI
1640 medium with stable L-glutamine (Invitrogen,
UK), supplemented with 2 % FBS. Human melano-
cytes used as healthy control cells were isolated from
foreskin. Foreskin was cut into small pieces and
incubated with 0.3 % trypsin (PAA) overnight at 4 C
and for 1 h at 37 C. Epidermis was separated. Cells
were mechanically removed from the cell layer and
centrifuged at 300 g for 3 min. The pellet was re-
suspended and cells further cultured in melanocyte
growth medium (Biomedica, Vienna, Austria, Promo-
Cell GmbH, Heidelberg, Germany). All cells were
kept in a 5 % CO2 atmosphere at 37 C. At 90 %
confluence cell-culture flasks were passaged after
detachment with accutase (PAA, Pasching Austria).
All cell cultures were periodically checked for
mycoplasma.
Toxicity studies: propidium iodide-uptake assay
Cells were collected, re-suspended in media and
diluted to a concentration of 106 cells/ml. Aliquots
of 105 cells/100 ll media were incubated with differ-
ent amount of peptides (0–80 lM) for 8 h at 37 C and
5 % CO2. Propidium iodide (PI) (2 ll/10
5cells of
50 lg/ml, Invitrogen, Camarillo, CA, USA) was
added and cells were again incubated for 5 min at
room temperature in the dark. Excitation and emission
wavelengths were 536 and 617 nm, respectively.
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Cytotoxicity was calculated from the percentage of PI
positive cells in media alone (P0) and in the presence
of peptide (PX). (see Eq. 1). Triton-X-100 was used to
determine 100 % of PI positive cells (P100).
%PI  uptake ¼ 100  ðPX  P0ÞðP100  P0Þ ð1Þ
Preparation of liposomes
Appropriate amounts of respective phospholipid stock
solution were dried under a stream of nitrogen and
stored in vacuum overnight to completely remove
organic solvents. The dry lipid film was then dispersed
in phosphate buffered saline (PBS, 20 mM NaPi,
130 mM NaCl, pH 7.4) and hydrated at a temperature
well above the gel to fluid phase transition of the
respective phospholipid under intermittent vigorous
vortex-mixing. The lipid concentration was 0.1
weight % for calorimetric and 2 % for leakage
experiments. Hydration was carried out in presence
or absence of peptides at a lipid-to-peptide ratio of
25:1 and 12.5:1 using a protocol described for POPS
(Jime´nez-Monreal et al. 1998), DPPS (Jing et al. 2005)
and DPPC (Sevcsik et al. 2007). Briefly hydration of
POPS films occurred at 30 C, DPPS at 65 C and
DPPC at 50 C, for 2 h with vortexing for 1 min every
15 min. The hydration of the lipid mixtures DPPS/
DPPC 1:5 and DPPS/DPPC 1:1 were performed at
65 C for 2 h by vortexing accompanied by one
freeze–thaw cycle every 15 min. The fully hydrated
samples were stored for at least 1 h at room temper-
ature until measurement.
Differential scanning calorimetry (DSC)
DSC experiments were performed with a differential
scanning calorimeter (VP-DSC) from MicroCal, Inc.
(Northhampton, MA, USA). Heating scans were
performed at a scan rate of 30 C/h (pre-scan thermo-
stating 30 min) with a final temperature of approxi-
mately 10 C above the main transition temperature
(Tm) and cooling scans at the same scan rate (pre-scan
thermostating 1 min) with a final temperature approx-
imately 20 C below Tm. The heating/cooling cycle
was performed three times. Enthalpies were calculated
by integration of the peak areas after normalization to
phospholipid concentration and baseline adjustment
using the MicroCal Origin software (VP-DSC
version). The phase transition temperature was defined
as the temperature at the peak maximum (McElhaney
1982).
Fluorescence spectroscopy
Fluorescence spectroscopy experiments were per-
formed using a SPEX Fluoro Max-3 spectrofluorim-
eter (Jobin–Yvon, Longjumeaum, France) and spectra
were analyzed with Datamax software.
Tryptophan quenching
Tryptophan fluorescence spectra were obtained at room
temperature using an excitation wavelength of 282 nm
and a slit width of 5 nm for excitation and emission
monochromators. Quenching of Tryptophan was carried
out in the presence and absence of phospholipid
liposomes (lipid-to-peptide ratio 25:1) using 0.1, 0.4
and 0.7 M acrylamide. The data were analyzed accord-
ing to the Stern–Volmer equation (Eq. 2):
F0=F ¼ 1 þ KSV Q½  ð2Þ
where F0 and F represent the fluorescence emission
intensities in the absence and presence of the quencher
molecule (Q) and KSV is the Stern–Volmer quenching
constant, which is a quantitative measure for the
accessibility of tryptophan to acrylamide (Tao and
Cho 1979).
ANTS/DPX leakage experiments
Leakage of aqueous contents from liposomes was
determined using the 8-aminonaphthalene-1,3,6-tri-
sulfonic acid/p-xylene-bis-pyridinium bromide
(ANTS/DPX) assay (Ellens et al. 1985). Lipid films
(preparation see above) were hydrated with 12.5 mM
ANTS, 45 mM DPX, 68 mM NaCl, 10 mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
at pH 7.4 following a standard procedure. Subse-
quently, the dispersions were extruded 20 times
through a polycarbonate filter (Millipore-IsoporeTM)
of 0.1 lm pore size to obtain LUVs. Unilamellarity
and size were tested by X-ray and dynamic light
scattering, respectively. The ANTS/DPX encapsulat-
ing vesicles were separated from free ANTS/DPX by
exclusion chromatography using a column filled with
SephadexTM G-75 (Amesham Biosciences) fine gel
swollen in an isosmotic buffer (10 mM HEPES,
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140 mM NaCl, pH 7.4). The void volume fractions
were collected and the phospholipid concentration
was determined by phosphate analysis (Bartlett 1959;
Broekhuyse 2005). The fluorescence measurements
were performed in 2 mL of the isosmotic buffer in a
quartz cuvette at 37 C. Aliquots of LUVs were
diluted with the isosmotic buffer to a final lipid
concentration of 50 lM. Fluorescence spectra were
obtained at 37 C using an excitation wavelength of
360 nm, an emission wavelength of 530 nm and a slit
width of 5 nm for both excitation and emission
monochromators. Fluorescence emission was
recorded as a function of time before and after the
addition of incremental amounts of peptide. The
fluorescence increase due to leakage and subsequent
dilution of quenched dye was measured after addition
of peptides. Peptides were added to final concentra-
tions of 2, 4 and 8 lM, corresponding to peptide-to-
lipid molar ratios of 1:25, 1:12.5 and 1:6.25, respec-
tively. Data are presented in terms of fluorescence
intensity (IF and were calculated using Eq. 3:
IF ¼ F  F0
Fmax  F0 ð3Þ
F is the measured fluorescence, F0 the initial fluores-
cence without peptide and Fmax the fluorescence
corresponding to 100 % leakage gained by addition
of 1 % Triton X-100.
Circular dichroism (CD) spectroscopy
Measurements were performed on a Jasco J 715
Spectropolarimeter (Jasco, Gross-Umstadt, Germany)
at room temperature using quartz cuvettes with an
optical path length of 0.02 cm. The CD spectra were
measured between 260 and 180 nm with a 0.2 nm step
resolution. To improve accuracy 5 scans were aver-
aged. Peptides were dissolved in 10 mM Hepes (pH
7.4) to a final concentration of 100 lM. Spectra were
measured in the absence and presence of 1 mM
sodium dodecyl sulfate (SDS) or 1 mM dod-
ecylphosphocholine (DPC) mimicking cancer and
healthy mammalian membranes, respectively. The
respective peptide-to-surfactant molar ratios were
1:25 and 1:100. Background signals were subtracted
after measurements. Percentage secondary structure
calculations were done using Dichroweb, CDSSR
Convolution Program using reference set 4 (Whitmore
and Wallace 2004, 2008).
PEP-FOLD: de novo peptide structure prediction
The peptide secondary structures and folding were
predicted by PEP-FOLD, an online resource for de
novo peptide structure prediction. PEP-FOLD pro-
vides pdb (protein data bank) files with representation
of macromolecular structure. Pdb files were visualized
by DSViewer Pro (Accelrys Software Inc.).
Results
In this study, we report on activity, respectively
selectivity of human lactoferricin derivatives for
melanoma and melanoma metastases over differenti-
ated non-tumorigenic counterparts as melanocytes
in vitro and in model systems. The for toxicity studies
used cell lines of melanoma (SBcl2) and melanoma
metastases (WM164) were recently shown to expose
the negatively charged lipid PS, whereas the non-
tumorigenic melanocytes, were shown to lack PS
exposure (Riedl et al. 2011a). The three peptides
studied LF11-322, 6-MO-LF11-322 and R-DIM-P-
LF11-322 (for primary sequence see Materials and
Table 1) were originally derived from the membrane
active peptide LF11 (FQWQRNIRKVR-NH2) (Zwey-
tick et al. 2006, 2011b).
Cancer toxicity and selectivity in vitro
Cytotoxic activity of the peptides towards melanoma
cells of primary (SBcl-2) and metastatic lesions
(WM164) and differentiated non-tumorigenic mela-
nocytes was determined by measurement of PI-uptake,
which only occurs when integrity of the cell mem-
brane is lost. Cells were incubated in media containing
serum for 8 h in the presence of peptides. Peptide
Table 1 Amino acid (aa) sequence, – number (no.) and net
charge of peptides LF11-322, 6-MO-LF11-322 and R-DIM-P-
LF11-322
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concentrations were varied from 0 to 80 lM. Fig. 1a,
b illustrate that LF11-322 is only minor active
against the melanoma cell line SBcl-2 with \10 %
killing at a peptide concentration of 80 lM, as well
as against melanocytes with a moderate twofold
selectivity for WM164 cells at 20 lM peptide
concentration (Fig. 1C). N-Acylation in the case of
6-MO-LF11-322 significantly improves cancer cell
toxicity. Nevertheless at its IC50 of *20 lM peptide
concentration it already kills *15 % of the non-
cancer melanocytes, again yielding a rather modest
threefold to fourfold specificity for cancer over non-
cancer cells (Fig. 1c). Interestingly the specificity of
6-MO-LF11-322 for cancer cells is sevenfold after
1 h (data not shown) but subsequently decreases to
threefold to fourfold after 8 h (Fig. 1c). The repeat
peptide R-DIM-P-LF11-322 is even more active
against SBcl-2 than the N-acylated peptide 6-MO-
LF11-322, but with increased specificity for cancer
cells. Already at a peptide concentrations of 20 lM,
R-DIM-P-LF11-322 yields more than 80 % PI
positive SBcl-2 cells, while only \1 % of differen-
tiated non-tumorigenic melanocytes are killed,
exhibiting a specificity higher than 1,000-fold for
cancer cells at this peptide concentration (see
Fig. 1c). The melanoma cell line of metastatic
lesions, WM164, tested at 20 lM R-DIM-P-LF11-
322 peptide concentration is also highly sensitive to
the peptide (specificity [500-fold) (Fig. 1c).
Activity and selectivity in model systems:
mechanistic and structural studies
Based on the fact that cancer membranes specifically
expose the negatively charged lipid PS (Riedl et al.
2011a; Utsugi et al. 1991) inclusively the peptide
sensitive tumor cell lines SBcl2 and WM164 (Riedl
et al. 2011a), different liposomal mimics of human
cancerous and non-cancerous cell membranes were
applied to study the respective membrane interaction
of peptides: DPPS and POPS, negatively charged
phospholipids exposed on the outer leaflet of plasma
membranes of cancer cells, and DPPC or POPC, a
zwitterionic phospholipid mimicking plasma mem-
branes of non-neoplastic cells. For circular dichroism
studies SDS and DPC were used as cancer or non-
cancer models, respectively.
Fig. 1 Peptide toxicity/PI-uptake of cancer and non-cancer cell
lines. a Concentration dependent cytotoxic activity of LF11-322
(filled circle), 6-MO-LF11-322 (open circle) and R-DIM-P-
LF11-322 (triangle) against melanoma cell line SBcl-2 after 8 h
of incubation with peptides; b Concentration dependent
cytotoxic activity against primary cultures of differentiated
non-tumorigenic melanocytes after 8 h of incubation with
peptides; c specificity of peptides at 20 lM peptide concentra-
tion after 8 h of incubation displayed as PI-uptake ratio of
melanoma SBcl-2 versus melanocytes and melanoma metasta-
ses WM164 versus melanocytes
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Differential scanning calorimetry: destabilization
of cancer and non-cancer model membranes
Consistently with published data (Lewis and McElha-
ney 2000), the temperature-dependence of the access
heat capacity of pure DPPS shows one phase transition
(Fig. 2 bottom) which corresponds to the main chain-
melting from the lamellar-gel (Lb) to the liquid-
crystalline (La) phase at 52.6 C. Addition of LF11-
322, 6-MO-LF11-322 and R-DIM-P-LF11-322 (25:1
lipid-to-peptide molar ratio) results in a decrease of the
main-transition enthalpy (DHm) of DPPS, but to
different extent: DSC thermograms show that LF11-
322 only slightly reduces the main transition enthalpy
of PS by 10 %. However, N-acylation such as 6-MO-
LF11-322 has a stronger effect leading to a reduction
of the transition enthalpy by 35 %. Obviously the
repeat sequence, in form of R-DIM-P-LF11-322, leads
to the most severe perturbance of the cancer mimic
DPPS, indicated by a strong decrease of the transition
enthalpy by 70 % (see Table 2). In the presence of all
peptides the main-transition temperature (Tm) shifts to
lower values, due to a destabilization of the gel phase.
Again the repeat sequence exhibits the by far strongest
effect by a decrease of the transition temperature by
nearly 5 C and a broad peak over the whole transition
range. The thermogram of the LF11-322 treated
liposome is split into at least two peaks due to
different peptide affected lipid domains, where the
lower temperature transition is presumably more
highly enriched in peptide, a peptide effect of the
non-acylated LF11-322 also observed with the bacte-
rial model system phosphatidylglycerol (Zweytick
et al. 2011b). Addition of the N-acylated peptide
6-MO-LF11-322 however causes a main peak at
decreased transition temperature and a smaller transi-
tion at 40.6 C, the latter most likely cannot be related
to the lamellar gel to liquid crystalline transition. This
is confirmed by the wide-angle X-ray (WAXS) pattern
(data not shown) of DPPS liposomes in presence of
6-MO-LF11-322 which shows existence of a small
fraction of fluid hydrocarbon chains already at 25 C,
which is the same at 46 C. At 46 C however WAXS
indicates less order of hydrocarbon chains in the
presence than in the absence of the lipopeptide. This is
again in line with DSC results showing a decreased
transition enthalpy in presence of this peptide and a
decreased main transition temperature suggesting
destabilization of the gel phase. The decrease of
cooperativity indicated by an increase of the transition
half-width (DT1/2) (Table 2) shown for all 3 endo-
therms is due to differentially severe loss of cooper-
ativity. Comparable results were observed for POPS
liposomes (data not shown). Importantly, the effect of
the repeat (double) sequence R-DIM-P-LF11 is much
higher than the effect of the single sequence LF11-322
at doubled concentration (?LF11-322; 12.5:1 lipid-to-
peptide ratio; Fig. 2, thin line), excluding a simple
concentration effect. This is in correlation with the
toxicity studies showing a much higher than double
cancer toxicity of R-DIM-P-LF11-322 comparing
with LF11-322.
Unlike DPPS and POPS thermograms of DPPC
exhibit two transitions (Fig. 2 top) as well in agree-
ment with published data (Koynova and Caffrey
1998). The transition at 34.6 C corresponds to the
pre-transition, from the lamellar-gel (Lb
0) to the ripple-
phase (Pb
0). The second transition can be attributed to
the main-transition at 41.3 C (from the ripple-phase
(Pb
0) to the liquid-crystalline (La) phase). In contrast to
DPPS and POPS, DPPC liposomes remain unper-
turbed by addition of LF11-322, even when the
Fig. 2 DSC thermograms of DPPC, DPPC/DPPS 1:5 (molar
ratio), DPPC/DPPS 1:1 (molar ratio) and DPPS in the absence
and presence of LF11-322 (light gray), 6-MO-LF11-322 (gray)
and R-DIM-P-LF11-322 (dark gray) (25:1, lipid-to-peptide
molar ratio thick lines, 12:1, lipid-to-peptide molar ratio thin
lines). For clarity, the DSC curves were displayed on the
ordinate by an arbitrary increment
Biometals (2014) 27:981–997 987
123
concentration of peptide is doubled (see Fig. 2;
Table 2) (LF11-322; 12.5:1 lipid-to-peptide molar
ratio) or upon addition of the repeat form R-DIM-P-
LF11-322, where only a slight loss of cooperativity
occurs indicated by a minor increase of the half width
of the transition. This goes in hand with the non-toxic
effect of these peptides on non-tumor cells, such as
melanocytes. Addition of 6-MO-LF11-322 to DPPC
liposomes (25:1 lipid-to-peptide molar ratio) however
results in some perturbance of DPPC membranes
displayed by a shoulder at decreased transition tem-
perature with decreased cooperativity (Table 2).
We also investigated by DSC the effect of the
peptides on liposomes composed of mixtures of
DPPC/DPPS (1:5 and 1:1, molar ratios). In the
presence of peptides in both mixtures the phase
transitions are shifted to lower temperatures closer to
the lower melting component DPPC (41.3 C), indi-
cating a preferential interaction with the component
DPPS. This is most significant in presence of 6-MO-
and R-DIM-P-LF11-322. However the N-acylated
peptide in the mixture with only 20 % DPPS (80 %
DPPC) already induced a strong broadening and
splitting of the transition that implies an interaction
with both lipid components. The peptide R-DIM-P-
LF11-322 in both mixtures induces a significant
thinning of the transition at reduced temperatures
and reduced enthalpies suggesting a strong but specific
interaction with DPPS only.
ANTS/DPX leakage: membrane permeabilization
The membrane permeabilizing effect of peptides
(2–8 lM) on cancer and non-cancer mimics was also
tested by induction of leakage of ANTS/DPX from
large unilamellar vesicles composed of POPS and
POPC, respectively.
As illustrated in Fig. 3a, addition of the different
peptides to POPS vesicles, mimicking cancer cell
membranes, leads to diverse release of ANTS/DPX.
N-acylation increases the weak ANTS/DPX release
induced by 4 and 8 lM LF11-322 (*20 % at highest
concentration 8 lM) by a factor of three up to *30
and 70 %, respectively. Whereas the repeat sequence
R-DIM-P-LF11-322 is most effective in terms of
permeability increase at all concentrations inducing
leakage up to 90–100 % at e.g. highest peptide
concentration.
Table 2 Thermodynamic parameters of DDPS (cancer cell mimic), DPPC (non-cancer cell mimic), and 1:5 and 1:1 (molar ratios)
mixtures thereof in the absence and presence of LF11-322, 6-MO-LF11-322 and R-DIM-P-LF11-322 at a lipid to peptide molar ratio
of 25:1 (unless otherwise noted) (ad Fig. 2)
DHpre (kcal/mol) Tpre (C) DHm (kcal/mol) Tm (C) T1/2 (C)
DPPC 1.0 34.6 9.1 41.3 0.19
?LF11-322 1.1 34.8 9.0 41.3 0.17
?LF11-322 (12.5:1) 1.0 34.5 9.2 41.3 0.26
?6-MO-LF11-322 0.4 34.6 9.1 (40.7)/41.3 0.26
?R-DIM-P-LF11-322 1.5 34.5 9.1 41.3 0.25
DPPC/DPPS 5:1 – – 9.0 42.6 0.89
?LF11-322 – – 10.1 42.4 0.80
?6-MO-LF11-322 – – 7.2/1.6 42.2/42.6 3.30/1
?R-DIM-P-LF11-322 – – 8.2 42.2 0.83
DPPC/DPPS 1:1 – – 9.8 44.8 2.21
?LF11-322 – – 8.3 44.2 2.42
?6-MO-LF11-322 – – 5.4 43.3 2.45
?R-DIM-P-LF11-322 – – 7.9 42.4 1.08
DPPS – – 9.9 52.6 0.65
?LF11-322 – – 4.7/4.5 49.3/50.9 1.7/1.4
?LF11-322 (12.5:1) – – 2.1/4.9 47.8/50.1 2.48
?6-MO-LF11-322 – – (0.7)a/5.9 (40.6)a/51.7 2.24
?R-DIM-P-LF11-322 – – 3.1 47.9 1.53
a Not related to main transition
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Fig. 3B demonstrates ANTS/DPX release from
pure POPC liposomes, mimicking non-cancerous cell
membranes. Obviously, addition of LF11-322 and
R-DIM-P-LF11-322 does not result in any significant
release of the fluorophore (\5 %). Only the N-
acylated peptide 6-MO-LF11-322 provokes also slight
leakage of POPC vesicles of about 20 % at a peptide-
to-lipid molar ratio of 1:6.25, providing only threefold
specificity for the cancer mimic. The repeat sequence
R-DIM-P-LF11-322 exhibits the highest activity for
the cancer mimic with up to 20-fold selectivity for
cancer over non-cancer mimics being again in good
correlation with its high specificity for cancer cells
in vitro.
Tryptophan quenching: peptide solubility
and penetration depth
Trp-emission properties like emission wavelength and
fluorescence quenching by acrylamide can be used to
study changes in solubility of peptides and localization
of Trp in different environments, as in solution or in
the presence of membranes composed of different
lipids. The emission spectra of the 1 Trp of LF11-322,
6-MO-LF11-322 and the 2 Trp of R-DIM-P-LF11-322
in buffer exhibit a maximum (kem,max) near 356 nm
(see Table 3). This is in agreement with the emission
maximum of Trp exposed to polar environment as e.g.
to solvent. Together with the high Stern–Volmer
constant of LF11-322, 6-MO-LF11-322 and R-DIM-
P-LF11-322 (KSV * 20 M
-1) in solution an absence
of peptide aggregation can be assumed. By comparing
Trp fluorescence in solution with fluorescence in the
presence of the cancer mimics POPS and DPPS (lipid-
to-peptide molar ratio 25:1) it is obvious that the
Stern–Volmer constant (KSV) is dramatically
decreased by all peptides tested with strongest effect
of the R-DIM-P-LF11-322. This observation gives
evidence for a proportionally less polar environment
of the Trp of the three peptides in the presence of the
cancer mimic PS indicating localization at the inter-
face of the PS bilayer or deeper. Additionally, a
significant blue shift of the emission wavelength could
be observed for LF11-322, 6-MO-LF11-322 and
R-DIM-P-LF11-322 giving as well evidence of pen-
etration of the Trp into the membrane interface. The
KSV for all peptides is lower in the presence of anionic
phospholipids with unsaturated (POPS) than saturated
(DPPS) fatty acyl chains, which seems feasible since
peptides can penetrate more easily in the less tightly
packed membranes of POPS. Besides acyl chains of
POPS are fluid at the experimental temperature,
whereas the acyl chains of DPPS are still in the gel
phase. The repeat sequence R-DIM-P-LF11-322
shows strongest changes in characteristics in both
systems indicating deepest penetration of the peptides
tested into the hydrophobic core of the cancer
membrane mimicking bilayer.
In agreement with the other model studies no effect
(no pronounced blueshift) was seen with peptides
LF11-322 and R-DIM-P-LF11-322 in the presence of
DPPC, the non-cancerous cell mimic, which implies
no membrane penetration of Trp in this mimic. Only
6-MO-LF11-322 also exhibits a blue shift in the
Fig. 3 ANTS/DPX leakage of LUVs composed of POPS
(a) and POPC (b) as a function of the concentration of LF11-
322 (filled circle), 6-MO-LF11-322 (open circle) and R-DIM-P-
LF11-322 (triangle). Concentration of LUVs was 50 lM and
temperature was kept at 37 C during measurements. Complete
lysis was determined by addition of Triton X-100 and zero levels
correspond to fluorescence before peptide addition
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presence of DPPC by 9 nm, indicating less specific
membrane interaction than by the other peptides.
Circular dichroism spectroscopy and PEP-FOLD:
secondary structure vs. activity and selectivity
By circular dichroism studies significant differences in
secondary structure of the three peptides in lipidic
environment were observed (Fig. 4). Only in solution
all peptides exhibit similar structural properties, being
mainly unstructured and showing b-sheet conforma-
tion and turns to similar extent (analyzed data Fig. 5a–
c). By 15 % the N-acylated peptide (Fig. 5b) exhibits
the highest though still minor proportion of a-helical
content in solution. Since CD-experiments in lipidic
environment as POPS or POPC deliver rather noisy
data, SDS was taken as negatively charged cancer and
DPC as neutral non-cancer mimic. Two different
peptide-to-lipid ratios were used, 1:25 to define
conditions comparable to model studies, 1:100 to
ensure complete binding of whole peptide amount,
rather comparable to conditions in vitro. Nevertheless
only LF11-322 (Fig. 5a) in the presence of SDS shows
some enhanced effect at higher peptide concentration.
The other peptides do not show any significant
structural changes at different concentrations, there-
fore it can be assumed that also at high peptide-to-lipid
ratios no or all peptide is bound. Strikingly the
selective peptides LF11-322 (Fig. 5a) and R-DIM-P-
LF11-322 (Fig. 5c) exhibit a significant increase of b-
sheet conformation in the presence of the cancer
mimic SDS, the a-helical content is even further
decreased. Moreover the structure of these peptides in
the presence of the healthy mimic DPC is comparable
to structure in solution, giving hint for a structure
dependent cancer selective toxicity of these peptides.
Strikingly only the less selective peptide 6-MO-LF11-
322 exhibits a significant increase of the a-helical
content to same extent in the presence of both cancer
and non-cancer mimic. The presence of SDS enhances
a positive band at 230 nm exhibited by LF11-322
(Fig. 4).
As can be seen in Fig. 6 the structure prediction
performed by the program PEP-FOLD (Maupetit et al.
2009, 2010; The´venet et al. 2012) (http://bioserv.rpbs.
univ-paris-diderot.fr/PEP-FOLD/) reveals a b-sheet
conformation for R-DIM-P-LF11-322, which is con-
form with CD spectra of the peptide in presence of
SDS. For the short peptide LF11-322, no a-helix or
Fig. 4 CD spectra of LF11-322, R-DIM-P-LF11-322 and
6-MO-LF11-322 in the presence of buffer (black), the non-
cancer mimic DPC (light grey) and the cancer mimic SDS (grey)
Table 3 Stern-Volmer quenching constant (KSV) and maxima of emission wavelength (kem,max) of LF11-322, 6-MO-LF11-322 and
R-DIM-P-LF11-322 in PBS, POPS, DPPS and DPPC membranes at a lipid to peptide ratio of 25:1
Peptide KSV in PBS (M
-1)
(kem,max) (nm)
KSV in POPS (M
-1)
(kem,max) (nm)
KSV in DPPS (M
-1)
(kem,max) (nm)
KSV in DPPC (M
-1)
(kem,max) (nm)
LF11-322 19.7 (354) 5.4 (338) 7.9 (334) 8.8 (354)
6-MO-LF11-322 24.5 (353) 4.5 (342) 7.0 (337) 10.5 (344)
R-DIM-P-LF11-322 19.1 (353) 4.1 (334) 4.3 (335) 13.2 (352)
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b-sheet structure is predicted, probably because the
amount of only 9 amino acids is too low for formation
of such structures. Two turns between Phe2 and Arg6
are proposed. It is also nicely demonstrated that the
b-sheet structure of R-DIM-P-LF11-322 can be sta-
bilized by formation of several possible hydrogen
bonds (H-bonds) (red dashed lines in Fig. 6).
Discussion
It has been shown that plasma membranes of cancer
cells selectively expose the negatively charged lipid PS
(Riedl et al. 2011a; Utsugi et al. 1991), which offers a
potent target for amphipathic cationic host defense
peptides (Papo and Shai 2005; Riedl et al. 2011b). In
the present study, we could ascribe the selective
antitumor activity of human lactoferricin derivatives to
the selective activity against the cancer cell mimic PS
(Table 4). A lipid rather than a receptor target would be
advantageous, to minimize the risk of generation of
resistance by mutagenesis upon application.
As shown in this study the non-acylated peptide
LF11-322 exhibited only weak activity against mel-
anoma cancer cell lines, whereas the N-acylated
derivative 6-MO-LF11-322 showed elevated and the
repeat sequence R-DIM-P-LF11-322 highest activity
of peptides studied. Only 6-MO-LF11-322 exhibited
also moderate toxicity for non-cancer melanocytes
though at respective elevated concentrations. So
derivative R-DIM-P-LF11-322 emerged to be a pep-
tide highly active and specific for cancer cells.
Propidium iodide-uptake of melanoma cells upon
incubation with peptides 6-MO-LF11-322 and
Fig. 5 Secondary structure distributions. Analysis of CD
spectra of free peptides LF11-322, 6-MO-LF11-322 and
R-DIM-P-LF11-322 in solution and in complex with SDS and
DPC micelles. Distribution of secondary structures of LF11-322
(a), 6-MO-LF11-322 (b) and R-DIM-P-LF11-322 (c) in Hepes
buffer (first bar) or presence of SDS and DPC at peptide to
surfactant ratios of 1:25 and 1:100 were calculated using
Dichroweb, CDSSR Convolution Program using reference set 4
(27;28). The a-helical content is shown in black at the bottom;
b-sheet in light grey; turns in dark grey; random coil structures
in white at the top
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R-DIM-P-LF11-322 further nicely demonstrates that
the peptides might operate via a membrane mediated
way, since propidium iodide can only be taken up by
cells that suffer membrane disintegration. Actually
host defense peptides are mainly described to act via a
non-receptor mediated pathway against the target cell
Fig. 6 Secondary structure predictions for peptide LF11-322
and R-DIM-P-LF11-322 were performed by use of the program
PEP-FOLD (Maupetit et al. 2009, 2010; The´venet et al. 2012).
The best model was plotted with DS ViewerPro 5.0 for
Windows. On the particular left sides the amino acids are
colored corresponding to their hydrophobicity according to the
whole residue (octanol) hydrophobicity scale by Wimley and
White (Wimley and White 1996). (hydrophilic amino acids are
colored in red, hydrophobic amino acids are colored in blue,
slightly charged amino acid Pro is colored in yellow). On the
particular right sides predicted secondary structures are plotted
and delineated, predicted hydrogen bonds are indicated as red
dashed lines
Table 4 Correlation of activity exhibited by peptides LF11-322, 6-MO-LF11-322 and R-DIM-P-LF11-322 in model and in in vitro
studies
Peptide LF11-322 6-MO-LF11-322 R-DIM-P-LF11-322
Amino acid sequence PFWRIRIRR-NH2 6-MO- PRRIRIRWFP-NH2
Net charge ?5 ?4 ?9
Hydrophobicity—DGwoct 5.64 3.34 7.12
Cancer mimic/healthy mimic
Bilayer perturbation—DSC ?/- ??/? ???/-
Permeability—ANTS/DPX leakage ?/- ??/? ???/-
Bilayer affinity—quenching ??/- ??/? ??/-
Main structure—CD b-sheet/as in solution a-helical/a-helical b-sheet/as in solution
Cancer cells/healthy cells
Toxicity—PI uptake -/- ??/? ???/-
Cancer specificity (?) ? - ????
For calculation of DGwoct of 6-MO-LF11-322 instead of the 6-MO residue N-acetylation was taken
a DGwoct [kcal/mol] Peptide hydrophobicity expressed as transfer free energy of peptides from water to n-octanol (DGwoct) calculated
from the whole-residue hydrophobicity scale taking in account the contribution of the C-terminal amide (Wimley and White 1996)
?, peptide effect; ??, increasing peptide effect; etc.; -, no peptide effect
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membrane by membranolytic effects; they can either
trigger necrosis or apoptosis of cancer cells (Papo and
Shai 2005; Riedl et al. 2011b). For triggering necrosis
they directly kill by disrupting the target plasma
membrane, whereas for triggering apoptosis they have
to selectively enter cancer cells and cause mitochon-
drial swelling with consequent release of cytochrome
c (Papo and Shai 2005). Bovine lactoferricin, e.g. was
shown to selectively induce apoptosis in human
leukemia and carcinoma cell lines (Mader et al. 2005).
The correlation of activity against bacteria with
activity on bacterial model systems for lactoferricin
derived peptides and their N-acylated derivatives was
shown recently (Zweytick et al. 2011b). However, as
reported increase of activity of LF11-322 by
N-acylation as 6-MO-LF11-322 on the bacterial model
system did not completely correlate with increase in
antimicrobial activity, which seems to be due to the
fact that elevated binding of N-acylated peptides to
lipopolysaccharides (LPS) of the outer membrane of
Gram-negative bacteria counteracts the elevated
membrane permeabilizing potency on the cytoplasmic
membrane (Zweytick et al. 2011b).). In this study
however we demonstrate that antitumor activity as
well as activity on the tumor model system PS is
improved by N-acylation to a similar extent. Therefore
it can be speculated that PS is a main target of the
peptide on human cancer membranes and peptides are
not reduced in their effective concentration by other
membrane components, like LPS on bacteria. 6-MO-
LF11-322, however did not only exhibit elevated
activity against the cancer model but also to some
extent against the non-cancer model PC correlating
with moderate toxicity also against non-cancer mel-
anocytes. A fact that goes conform with elevated
hemolytic activity already described for N-acylated
derivatives of LF11 as 6-MO-LF11-322 (20 % lysis of
2.5 % RBCs at 500 lg peptide/ml, (Zweytick et al.
2011b)) or C12LF11 (85 % lysis of 0.25 % RBCs at
100 lg peptide/ml (Zweytick et al. 2006)). Lower
specificity might be due to increased peptide hydro-
phobicity by N-acylation indicated by a decrease of
transfer free energy (DGwoct) of peptides from water to
n-octanol (Wimley and White 1996), from 5.64 to
3.34 kcal/mol (see Table 4).
However, the repeat derivative of LF11-322,
R-DIM-P-LF11-322, exhibits even less hydrophobic-
ity (DGwoct 7.12 kcal/mol) than LF11-322, but highly
improved activity against cancer cell lines without loss
of selectivity. It has been reported by Yang et al. (Yang
et al. 2004) that a prerequisite for antitumor but not for
antibacterial peptides derived of bovine lactoferrin is a
minimum net charge close to ?7 and to consist of at
least 14 amino acids. And really, LF11-322 (9 amino
acids; net charge ?5) exhibited considerable antibac-
terial activity with a minimal inhibitory concentration
for E. coli of 8–16 lg/ml (Zweytick et al. 2011b) but
only negligible antitumor activity. We therefore
designed R-DIM-P-LF11-322 (19 amino acids; net
charge ?9) a peptide composed of the peptide moiety
LF11-322 linked to itself retro sequence via peptide
bond over the amino acid Pro as a linker. The peptide
moiety sequence was taken as template because it was
not toxic for normal cells and the retro sequence added
with a Pro linker should further help to stabilize the
peptide structure via hydrogen bonds. The idea of
addition of the retro sequence is to design a ‘‘twin’’-
peptide with increased amphipathicity. And actually
cancer-toxicity is highly increased, in fact much more
than doubled, by the repeat sequence peptide and like
shown for the N-acyl derivative improved interaction
of R-DIM-P-LF11-322 with the cancer mimic PS
correlates with increased activity against the mela-
noma cancer cell line. Also no interaction with the
healthy mimic PC correlates with no toxicity against
non-cancer cells. R-DIM-P-LF11-322 seems to exhi-
bit a high membrane destabilization effect together
with highly increased induction of membrane perme-
ability of PS bilayers. Besides, permeability studies
show that a certain threshold concentration of the
peptide is needed for induction of sufficient leakage of
ANTS/DPX, differentiating it from highly lytic but
mostly unspecific peptides like melittin, which
induces leakage already at very low concentrations
(data not shown) (Papo and Shai 2005). As mentioned,
by model studies, such as calorimetry or ANTS/DPX
leakage and in vitro studies it could be demonstrated
that the effect of the repeat sequence peptide is even
much higher than that of the peptide moiety at double
concentration, excluding a simple mass and charge
effect. As shown in model studies with mixtures of
DPPC and DPPS the peptide R-DIM-P-LF11-322
seems to be able to act on the cancer membrane by
specific clustering of the PS component, indicated by a
strong decrease of Tm and T1/2 of the mixture, a
mechanism also described for antimicrobial peptides
as gramicidin S, magainin, PGLa and others (Epand
et al. 2010; Wadhwani et al. 2012).
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Trp localization studies of the 3 peptides showed
that if a peptide is active against a certain membrane
lipid, it exhibits a significant blue shift of the Trp
emission wavelength upon interaction with the mem-
brane indicating a more hydrophobic environment of
Trp due to interaction with the membrane interface. In
the case of the repeat sequence peptide this blue shift
only occurs in presence of the target lipid PS present
on the surface of cancer membranes, whereas in the
presence of PC no blue shift appears, going in hand
with a selective toxicity against cancer cells in vitro.
The N-acylated peptide however reveals a blue shift in
the presence of both model systems though the
accessibility of Trp (Ksv) is more highly decreased in
the presence of the cancer mimic, again resembling
activity in vitro, where 6-MO-LF11-322 is also
slightly active against non-cancer cells. Also leakage
experiments show that membrane permeabilizing
specificity of 6-MO-LF11-322 for the cancer model
system, which is threefold over the non-cancer model,
resembles the relatively low threefold specificity for
melanoma cells in vitro, a very good demonstration of
the correlation of the model studies with biological
activity (see Table 4).
Further information on the studied peptides was
given by CD measurements and secondary structure
predictions. The differences between the selective and
non-selective peptides were quite obvious. Significant
structural changes for LF11-322 and the repeat
sequence peptide appear only in the presence of the
negatively charged cancer mimic SDS. The N-acyl-
ated peptide again changes its structure in environ-
ment of both models correlating with its lower
specificity. Although structural studies in the presence
of SDS and DPC forming micelles cannot be abso-
lutely compared to changes in the presence of a
bilayer, the changes can be correlated to changes
induced by the outer monolayer of the cancer or non-
cancer cell membranes, which is the first and most
important point of interaction. Strikingly only the N-
acylated less selective peptide shows an increase of the
a-helical content in the presence of both model
systems, differently LF11-322 and R-DIM-P-LF11-
322 show an increase of the b-sheet content but as
mentioned only in presence of the cancer model SDS.
According to a cluster analysis of Dennison et al.
(2010) out of 158 amphipathic a-helical peptides
*80 % were shown to be toxic to both cancer and
non-cancer cells. Such a tilted structure has also been
associated already earlier with relatively non-specific
means of cell membrane lysis (Hoskin and Rama-
moorthy 2008). Interestingly however only 2 % of all
antitumor peptides listed (Wang et al. 2009; Wang and
Wang 2004) exhibit a b-sheet structure (Riedl et al.
2011b), though being quite successful in in vitro and
in vivo studies. Antitumor peptides with b-hairpin
structure are e.g., natural bovine lactoferricin (Hwang
et al. 1998) or designed SVS-1 (Sinthuvanich et al.
2012).
From the differences in in vitro activity displayed
by the peptide moiety and the repeat sequence peptide
it was however surprising that both peptides show
quite similar structural characteristics in solution and
model system. Considering the shortness of LF11-322,
it is even questionable that a b-sheet conformation, as
proposed by CD data, is possible. Secondary structure
prediction (PEP-FOLD, Fig. 6) performed for the
short peptide LF11-322 indicates that the peptide
forms two turns between Phe2 and Arg6. This is in
agreement with previous NMR data that peptide
LF11-322 forms a helical turn between residues 3-6
in the presence of SDS micelles (Zorko et al. 2009).
However, maybe the peptide moiety is too short to
form an as stable secondary structure as in comparison
to R-DIM-P-LF11-322 which is predicted to adopt a
b-hairpin structure. It is moreover reasonable that two
peptide moiety stretches might arrange like a dimer
(polymer) and thereby arrange in loose b-sheets
stabilized by H-bonds. The repeat sequence peptide
however is fixed in this conformation via peptide bond
and is able to create stronger membrane perturbance
and finally higher membrane permeabilization, which
can explain its highly increased activity in model and
cell system. This theory of an arrangement of LF11-
322 like a polymer is maybe supported by the fact that
the CD spectra of LF11-322 in solution and even more
in presence of SDS exhibit a positive band at 230 nm.
In literature such a band is described as a hallmark for
a polyproline type II (PPII) helix (Woody 1992). Such
structures are common in e.g. unfolded polypeptides
(Shi et al. 2002). Nevertheless from model studies,
LF11-322 could be reasoned to be more active than
in vitro studies show. Minor activity in vitro could
therefore also be due to minor stability of the peptide
moiety considering that proteins with N-terminal Pro
amongst others are described to exhibit short half-lives
of half an hour (Westphal et al. 2003). Proteolytic
instability could on the one hand be the reason for the
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low activity of the peptide moiety and proteolytic
protection by structural conformation, on the other
hand explain the highly increased activity of the repeat
sequence R-DIM-P-LF11-322. A stable structure of
bovine Lactoferrin has been reported before to be a
prerequisite for antitumor even more than for antimi-
crobial activity (Bellamy et al. 1992; Schibli et al.
1999; Yang et al. 2004). To check stability we tested
activity of LF11-322 in the presence of buffer and
absence of serum and could not detect any improve-
ment of activity after 1 h (data not shown). We chose
such a short period to prevent membrane effects
caused by growth deficiencies due to lack of serum
components. However selective peptides that act over
apoptosis rather than necrosis probably need longer
time periods for killing, which might hinder the clear
conclusion of this experiment. CD data of the N-acyl
derivative 6-MO-LF11-322 show an increase of the
a-helical proportion of the peptide in presence of SDS
and DPC. 2D-NMR of a related lipopeptide, N-lauryl-
LF11, indicated a more defined structure in presence
of SDS than in DPC (Japelj et al. 2007). However, a
defined structure of the peptide was shown to be
stabilized by the N-acyl group, which might also have
impact on the increased antitumor activity of 6-MO-
LF11-322.
A proposed model for the interaction of the studied
peptides with cancer membranes is the following:
Peptides first are attracted to the cancer membrane by
electrostatic interaction with PS (Gifford et al. 2005;
Papo and Shai 2005). The fact that activity on WM164
was slightly weaker than activity against SBcl-2,
though WM164 exposes higher levels of PS (*three-
fold) than SBcl-2 (Riedl et al. 2011a; Zweytick et al.
2011a), suggests that the degree of antitumor activity
does not seem to go in hand with the degree of PS
exposed. Probably just an elevated (threshold) level of
PS exposed compared to non-cancer cells is required
for antitumor activity. However other negative
charges on the cancer surface as targets as exhibited
by sialic acid residues, which appear to be linked to
some glycoproteins (e.g. mucins) and glycolipids
present on membrane surfaces and are partially
overexpressed within certain cancer types, do not
seem to interfere with the LF11 derived peptide
activity, which was demonstrated by maintenance of
activity after sialidase treatment (manuscript Riedl
et al. in preparation). At a certain concentration the
peptides once attracted to the negatively charged PS
on the cancer membrane seem to penetrate with their
hydrophobic amino acids like an anchor into the
membrane. This can lead to direct (fast) membrane
lysis, which in the case of the N-acylated peptide
partially might occur, probably also due to its high
hydrophobic moiety. This to some degree also causes
interaction with neutral lipids on cancer and as well on
non-cancer membranes. The repeat sequence however
can due to its adoption of a defined structure only in
the presence of PS specifically interact with cancer
membranes. Probably it enters the membrane selec-
tively over the PS key and then interacts with inner
lipid targets causing apoptosis. This idea is also
supported by the fact that the repeat sequence is acting
more slowly than the N-acylated peptide (data not
shown), which lets preferentially assume a killing
mechanism via apoptosis.
In our study we could prove that quite low
hydrophobicity but a prolonged sequence combined
with a higher net positive charge are sufficient or
needed to improve the antitumor activity of hLFcin
derivatives. Conformational changes exclusively in
the presence of the target membrane seem to induce
selective activity. As can be seen by the N-acylated
peptide improvement of activity by increase of the
hydrophobic moiety also might implicate increased
effect on neutral membrane components and there-
fore also provoke toxicity against healthy non-
cancer cells. Adoption of a stable secondary struc-
ture however seems to be possible within the repeat
sequence peptide R-DIM-P-LF11-322 compared to
the short peptide LF11-322 resulting in high and
selective toxicity on cancer cells in vitro. In
conclusion, we were able to demonstrate a signif-
icant correlation between the toxicity of the studied
peptides against human cancer or non-cancer cells
and interaction with the respective model membrane
systems, proving PS as a molecular target of the
peptides on cancer cells. Such a specific marker
offers the possibility of treatment of all cancer
types, also with so far poor treatability, and even
metastases with minimization of side effects and
formation of resistance.
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